Literature DB >> 22015058

Targeted therapy for patients with renal-cell carcinoma.

Brian I Rini1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22015058     DOI： 10.1016/S1470-2045(11)70276-5

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  6 in total

1.  The 2019 Nobel Prize honors fundamental discoveries in hypoxia response.

Authors:  Javid Moslehi; W Kimryn Rathmell
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

2.  Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.

Authors:  Roberto Pili; Glenn Liu; Sreenivasulu Chintala; Hendrick Verheul; Shabnam Rehman; Kristopher Attwood; Martin A Lodge; Richard Wahl; James I Martin; Kiersten Marie Miles; Silvia Paesante; Remi Adelaiye; Alejandro Godoy; Serina King; James Zwiebel; Michael A Carducci
Journal:  Br J Cancer       Date:  2017-02-21       Impact factor: 7.640

3.  Overexpression of HHLA2 in human clear cell renal cell carcinoma is significantly associated with poor survival of the patients.

Authors:  Lujun Chen; Dawei Zhu; Jun Feng; You Zhou; Qi Wang; Huijing Feng; Junping Zhang; Jingting Jiang
Journal:  Cancer Cell Int       Date:  2019-04-16       Impact factor: 5.722

4.  Multiparameter Evaluation of the Platelet-Inhibitory Effects of Tyrosine Kinase Inhibitors Used for Cancer Treatment.

Authors:  Bibian M E Tullemans; Alicia Veninga; Delia I Fernandez; Maureen J B Aarts; Johannes A Eble; Paola E J van der Meijden; Johan W M Heemskerk; Marijke J E Kuijpers
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

Review 5.  Individualising treatment choices in a crowded treatment algorithm.

Authors:  Rosalie Fisher; James Larkin
Journal:  EJC Suppl       Date:  2013-09

6.  AHNAK2 is a Novel Prognostic Marker and Oncogenic Protein for Clear Cell Renal Cell Carcinoma.

Authors:  Minglei Wang; Xuefeng Li; Jin Zhang; Qiong Yang; Wenqi Chen; Weilin Jin; Yi-Ran Huang; Ru Yang; Wei-Qiang Gao
Journal:  Theranostics       Date:  2017-02-27       Impact factor: 11.556
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.